Lipid-Rich Necrotic Core Linked to Psoriasis Severity
TUESDAY, Sept. 15, 2020 -- For patients with psoriasis, lipid-rich necrotic core (LRNC) is associated with psoriasis severity and cardiovascular risk factors and is reduced for those patients receiving biologic therapy, according to a study published online Sept. 15 in Circulation: Cardiovascular Imaging.
Harry Choi, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues characterized LRNC in 209 biologically naive psoriasis patients who underwent coronary artery computed tomography angiography at baseline and one year. Histopathologically validated software was used to assess changes in LRNC before and after biologic therapy over one year.
The researchers found that LRNC was associated with Framingham risk score and psoriasis severity in all participants at baseline. At one year, a reduction in LRNC was seen in participants receiving biologic therapy (3.12 versus 2.97 mm²), while no significant change was seen for those who did not receive biologic therapy (3.12 versus 3.34 mm²). Compared with the change in the non-biologic-treated group, the change in LRNC in those receiving biologic therapy was significant (−0.22 versus 0.14 mm²); after adjustment for cardiovascular risk factors and psoriasis severity, the change remained significant.
"We specifically demonstrated the beneficial effects of biologic therapy on LRNC, and these findings provide important insight into the potential stabilization and reversibility of LRNC in the coronary artery," the authors write.
Several authors disclosed financial ties to the biopharmaceutical industry.
© 2021 HealthDay. All rights reserved.
Posted September 2020
Read this next
FRIDAY, July 30, 2021 -- Prepregnancy cardiovascular risk factors are highly prevalent and are associated with adverse maternal and fetal outcomes, according to a research letter...
THURSDAY, July 29, 2021 -- Metabolic syndrome and some of its components are associated with stroke recurrence, according to a review published online July 28 in...
WEDNESDAY, July 21, 2021 -- Cancer survivors, especially survivors of hematologic malignancies, have an increased risk for psoriasis, according to a research letter published...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.